Hemophilia B

Disease State Hub

News
Research Summaries
Resources
FDA Alerts Pearls of Wisdom From the Journal
Insights
Commentary Podcasts Q&As Videos
Interactive
Polls Quizzes Slideshows
Events & Education

FDA Alerts

Liver Disease
Liver Disease
FDA Expands Approved Use of Stivarga
04/27/2017
The FDA has approved the first new option for the treatment of liver cancer, specifically hepatocellular carcinoma, in nearly 10 years.
04/27/2017
Liver Disease
Liver Disease
FDA Expands Approved Use of Stivarga
04/27/2017
The FDA has approved the first new option for the treatment of liver cancer, specifically hepatocellular carcinoma, in nearly 10 years.
04/27/2017
Liver Disease
Liver Disease
FDA Expands Approved Use of Stivarga
04/27/2017
The FDA has approved the first new option for the treatment of liver cancer, specifically hepatocellular carcinoma, in nearly 10 years.
04/27/2017
opioids
opioids
Abuse-Deterrent Opioid Receives FDA Approval
04/26/2017
The first immediate-release opioid to receive abuse-deterrent labeling was recently approved by the FDA.
04/26/2017
opioids
opioids
Abuse-Deterrent Opioid Receives FDA Approval
04/26/2017
The first immediate-release opioid to receive abuse-deterrent labeling was recently approved by the FDA.
04/26/2017
opioids
opioids
Abuse-Deterrent Opioid Receives FDA Approval
04/26/2017
The first immediate-release opioid to receive abuse-deterrent labeling was recently approved by the FDA.
04/26/2017
FDA
FDA
FDA Approves First Methotrexate Oral Solution
04/26/2017
The FDA has approved Xatmep, an oral solution for the treatment of acute lymphoblastic leukemia and polyarticular juvenile idiopathic arthritis.
04/26/2017
Lipids
Lipids
FDA Approves New Dosing Option for Praluent
04/25/2017
The FDA has approved a new, monthly dosing option for the PCSK9-inhibitor Praluent (alirocumab).
04/25/2017
Lipids
Lipids
FDA Approves New Dosing Option for Praluent
04/25/2017
The FDA has approved a new, monthly dosing option for the PCSK9-inhibitor Praluent (alirocumab).
04/25/2017
Lipids
Lipids
FDA Approves New Dosing Option for Praluent
04/25/2017
The FDA has approved a new, monthly dosing option for the PCSK9-inhibitor Praluent (alirocumab).
04/25/2017